Cargando…

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL

Detalles Bibliográficos
Autores principales:	Perez, Ariel, Johnson, Grace, Patel, Kedar, Arciola, Brian, Wood, Anthony, Bachmeier, Christina A., Chavez, Julio C., Shah, Bijal D., Khimani, Farhad, Nishihori, Taiga, Lazaryan, Aleksandr, Davila, Marco L., Mhaskar, Rahul, Locke, Frederick L., Gaballa, Sameh, Jain, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278282/ https://www.ncbi.nlm.nih.gov/pubmed/35816359 http://dx.doi.org/10.1182/bloodadvances.2022007006

Ejemplares similares

Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study
por: Lee, Dae Hyun, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1540: COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE
por: Din, Mohammad Ammad Ud, et al.
Publicado: (2023)

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
por: Logue, Jennifer M., et al.
Publicado: (2020)

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
por: Hoogland, Aasha I., et al.
Publicado: (2021)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

CIT
por: Odom, Sean
Publicado: (2004)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
por: Verburg-Baltussen, E. J., et al.
Publicado: (2022)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
por: Munoz, Javier, et al.
Publicado: (2023)

Op. cit.
por: Deniz, Gerardo, 1934-2014

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
por: Ionescu, Filip, et al.
Publicado: (2022)

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
por: Ionescu, Filip, et al.
Publicado: (2023)

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
por: Lazaryan, Aleksandr, et al.
Publicado: (2022)

Citrus CitNAC62 cooperates with CitWRKY1 to participate in citric acid degradation via up-regulation of CitAco3
por: Li, Shao-jia, et al.
Publicado: (2017)

P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.
por: Dodero, A., et al.
Publicado: (2022)

How sweet! Transcription factor CitZAT5 regulates CitSUS5 and CitSWEET6 to promote sugar accumulation in citrus fruit
por: Ku, Yee-Shan
Publicado: (2023)

Evolution and transformation of JVS-CIT
por: Gloviczki, Peter, et al.
Publicado: (2021)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
por: Bücklein, Veit, et al.
Publicado: (2023)

PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mohammed, Turab, et al.
Publicado: (2023)

Alyon, Cit., on the Medical Properties of Oxygen
Publicado: (1798)

Involvement of CitCHX and CitDIC in Developmental-Related and Postharvest-Hot-Air Driven Citrate Degradation in Citrus Fruits
por: Lin, Qiong, et al.
Publicado: (2015)

Transcription Factor CitERF16 Is Involved in Citrus Fruit Sucrose Accumulation by Activating CitSWEET11d
por: Hu, Xiaobo, et al.
Publicado: (2021)

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation
por: Betts, Brian C., et al.
Publicado: (2017)

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
por: Weinstein, Bayarmagnai, et al.
Publicado: (2021)

High antigen density of BCMA: friend or foe to CAR T cells?
por: Gaballa, Mahmoud R, et al.
Publicado: (2022)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

The Interaction Between CitMYB52 and CitbHLH2 Negatively Regulates Citrate Accumulation by Activating CitALMT in Citrus Fruit
por: Liu, Shengchao, et al.
Publicado: (2022)

Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review
por: Nishihori, Taiga, et al.
Publicado: (2017)

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation
por: Pidala, Joseph, et al.
Publicado: (2018)

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma
por: Lee, Dae Hyun, et al.
Publicado: (2022)

Transcription factor CitERF71 activates the terpene synthase gene CitTPS16 involved in the synthesis of E-geraniol in sweet orange fruit
por: Li, Xiang, et al.
Publicado: (2017)

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
por: Chavez, Julio C., et al.
Publicado: (2019)

Proposed diagnostic data acquisition, monitor and control system for CIT
por: Rauch, W, et al.
Publicado: (1990)

Up-regulation of CIT promotes the growth of colon cancer cells
por: Wu, Zehua, et al.
Publicado: (2017)

Extracts from Cit. Lombart's Observations on Chirurgical Cases, &c.
Publicado: (1799)

Cannot write session to /tmp/vufind_sessions/sess_cfpvqi2kiajs3sspq18brtscdf